Heparin-Binding Peptides Block Viral Entry via Competitive Binding
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current therapeutics for viral infections, such as HSV and CMV, face challenges including increased viral resistance and harmful side effects, necessitating the development of less toxic and resistant-free treatments that target the heparan sulfate-mediated viral entry process.
Innovation Solution
Administration of heparin-binding peptides, such as GGGY-p5+14, which bind to cell surface heparan sulfate, inhibiting viral attachment and entry by competing with viruses for binding sites, thereby reducing infection without direct viral neutralization.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current antiviral drugs are used to treat viral infections, then viral infection is inhibited, but viral resistance increases and harmful side effects occur
Solution Approach 1:
The patent uses heparin-binding peptides as intermediary molecules that compete with viruses for binding to heparan sulfate on cell surfaces. These peptides act as mediators that block viral attachment without directly interacting with viral replication machinery, thereby preventing resistance development while maintaining antiviral efficacy.
Solution Approach 2:
The invention creates synthetic copies of the heparin-binding domain that mimic the natural binding interaction between viruses and heparan sulfate. By copying the essential binding feature and using it in a therapeutic context, the peptides block viral attachment through competitive binding without requiring direct viral neutralization.
2Reliability
If heparin-binding peptides are administered to block viral entry, then viral attachment is inhibited, but the mechanism must specifically target heparan sulfate binding
Solution Approach 1:
The peptides are designed with specific local properties - a high density of positively charged amino acid residues (arginine and lysine) concentrated in a specific region of the peptide structure. This local concentration of positive charges creates a focused electrostatic interaction with the negatively charged heparan sulfate, achieving high specificity without requiring complex multi-component systems.
Solution Approach 2:
The invention modifies the chemical parameters of the peptide by adjusting the ratio and arrangement of charged versus neutral amino acids. By optimizing the positive charge density and distribution, the peptides achieve optimal binding affinity for heparan sulfate while maintaining solubility and biological compatibility, thereby achieving specific viral entry blockage.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The heparin-binding peptides effectively inhibit viral infections by reducing viral plaque formation and infectivity, demonstrating a significant reduction in CMV, HCMV, and HSV infections, with a low probability of resistance development.
Implementation Method 1
The versatility of HS to bind multiple microbes and participate in a variety of regulatory phenomena comes from its negatively-charged nature... heparin-binding peptides... bind to cell surface heparan sulfate
Data Source
AI summary
Disclosed are methods of treating and/or inhibiting a viral infection in a subject. The methods include administering a therapeutically effective amount of heparin-binding peptide. Also disclosed herein are methods for blocking viral binding to a cell. Further disclosed are anti-viral compositions for administration to a subject infected with a virus. Administration of the anti-viral composition inhibits viral infection of the subject.